References
- Co-operative Group for the Study of Intravenous Immunoglobulin. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988; 319: 902–907
- Chapel H M, Lee M, Hargreaves R, Pamphilon D H, Prentice A G. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994; 343: 1059–1063
- Anonymous. Consensus on IVIG. Lancet 1990; 336: 470–472
- Chapel H M, Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp Immunol 1994; 97(Suppl 1)21–24
- Higgins J PT, Greene R. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. John Wiley & Sons Ltd., ChichesterUK 2006; 4
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188
- Chapel H, Griffiths H, Brennan V, Bunch C, Lea J, Lee M. Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy. Immunol Invest 1991; 20: 187–191
- Chapel H M, Hargreaves R, Lee M, Pamphilon D. Intravenous immunoglobulin therapy in patients with multiple myeloma. Immunodeficiency 1993; 4: 77–78
- Gamm H, Huber C, Chapel H, Lee M, Ries F, Dicato M A. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol 1994; 97(Suppl 1)17–20
- Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73: 366–368
- Salmon S E, Samal B A, Hayes D M, Hosley H, Miller S P, Schilling A. Role of γ globulin for immunoprophylaxis in multiple myeloma. N Engl J Med 1967; 277: 1336–1340
- Weeks J C, Tierney M R, Weinstein M C. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81–86
- Boughton B J, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995; 17: 75–80
- Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 1994; 88: 209–212
- Gluck S, Schnutenhaus W, Schneider W. Prophylactic intravenous immunoglobulin (IVIG) application to patients with recurrent infections and secondary antibody deficiency due to B-cell neoplasia. Blut 1990; 61: 140
- Hargreaves R M. Infection, immune responses and intravenous immunoglobulin infection prophylaxis in myeloma. Br J Cancer 1992; 66: 11
- Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81: 121–126
- Musto P, Brugiatelli M, Carotenuto M. Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol 1995; 89: 945–946
- Sklenar I, Schiffman G, Jonsson V, Verhoef G, Birgens H, Boogaerts M, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 1993; 50: 466–477
- Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 817–835